REGULATORY

First Generics for 18 APIs Join NHI Price List; Patent Row-Hit Edirol Gx, 7 AGs Included

June 19, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) on June 19 added first generics for 18 APIs to the NHI price list, which include generic versions of Chugai Pharmaceutical’s osteoporosis treatment Edirol Capsules (eldecalcitol) despite an ongoing patent infringement lawsuit.…

To read the full story

Pfizer Launches Celecox Authorized Generic, Its 1st AG
June 22, 2020
5 Authorized Generics Hit Japan Market on June 19
June 19, 2020

REGULATORY

Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…